May 11, 2020
VIVA Physicians Publishes Analysis Evaluating Mortality and Paclitaxel-Coated Devices
Mar 25, 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea® from Oasmia Pharmaceutical
Oct 22, 2019
Global Bulk Paclitaxel Industry
Jul 01, 2019
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Jun 24, 2019
Update on FDA Panel Meeting on Paclitaxel Coated Products
May 22, 2019
United States $20 Bn Breast Cancer Drug Market to 2025: 42 Marketed Drugs, 317 Drugs in Clinical Pipeline by Company, Phase, Drug Class & Patient Segment
Mar 20, 2019
Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer
Sep 12, 2018
Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer
Jun 01, 2018
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
Apr 30, 2018
AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology
Apr 20, 2018
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Feb 15, 2018
Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2018-2024 - Favorable Market Parameters & Commercialization Challenges
Dec 08, 2017
Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
Oct 16, 2017
Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
Sep 10, 2017
Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
Jun 26, 2017
Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
Jun 26, 2017
NewVac Presented Results of Quisinostat's Phase II Clinical Trial at ASCO 2017
Jun 09, 2017
Yew Bio-Pharm Group Announces the Launch of Its New E-Commerce Website
Jun 04, 2017
Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
May 31, 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival